New Companies
Filter News
Found 3,706 articles
-
Seattle startup AltPep targets amyloid deposits to treat Alzheimer's Disease.
-
Biopharma companies raking in the cash with investment rounds and IPO announcements.
-
Captivate Bio Launches with First Round of High-Quality Cell Culture Tools
1/14/2021
Captivate Bio, a newly formed scientific solutions provider headquartered in Watertown, Massachusetts, emerged from stealth mode today to announce it has successfully launched its portfolio of cell culture tools to assist in the fight against COVID-19 and other emerging diseases as well as help address the gaps e
-
adMare Launches Abdera with AbCellera as a Founding Partner
1/14/2021
adMare BioInnovations, Canada's global life sciences venture, is pleased to announce the launch of Abdera Therapeutics Inc. (Abdera) with founding partner, AbCellera (Nasdaq: ABCL)
-
Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the company’s cell-based therapy discovery and development operations.
-
Flagship Pioneering launched a new company called Inzen Therapeutics, which will discover and develop a new class of medicines based on a new area of biology that will provide new therapeutic approaches to multiple types of diseases.
-
Bluebird bio announced plans to split its genetic disease and oncology businesses. Bluebird bio will stay focused on severe genetic disease and spin out its oncology business into a new company.
-
RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.
-
Cyclolab and EpiPharma Form Joint Venture company Targetrin Therapeutics to Develop and Commercialize novel conjugated Cyclodextrin – Peptide drugs
1/11/2021
Cyclolab and EpiPharma announced that the companies have signed an agreement to form a joint venture specialty pharmaceutical company to develop and commercialize novel conjugated Cyclodextrin – Peptide drug candidates for the treatment of debilitating CNS and Pulmonary diseases.
-
Mana Therapeutics takes aim at solid tumors with allogenic cell therapies and Aulos Bioscience sees a new path for IL-2 monoclonal antibodies.
-
ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
1/8/2021
ATP, a leading life sciences venture capital firm, and Biolojic Design, a biotechnology company that computationally designs functional antibodies, today unveiled Aulos Bioscience, a new company that is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors
-
AI gives you a chance to prevent Alzheimer's Dementia
1/8/2021
AI brain mapping with EEG discovered Alzheimer's brainwave and could detect preclinical Alzheimer's dementia(AD). This has been enabled by an innovative AI technology of iMediSync in brain mapping. iMediSync, a biotech startup launched EEG digital biomarker for early detection of Alzheimer's de
-
Veteran Biopharma Executive Dane D. Hallberg Launches MASORI Therapeutics
1/7/2021
New company will leverage artificial intelligence to help clients in multiple sectors generate actionable market insights and create competitive advantage
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Meiji Seika Pharma Sets up a New Subsidiary in the US
1/5/2021
Meiji Seika Pharma Co., Ltd. announces the starting of operation of its US subsidiary, Meiji Pharma USA Inc., for expanding activities in the US with its initial focus on facilitating clinical development.
-
Therapeutic Solutions International Launches Campbell Neurosciences Inc as First Suicide Focused Regenerative Psychiatry Biotechnology Company
12/31/2020
Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today the launching of Campbell Neurosciences Inc as a partially owned spin-off from the Company.
-
rBIO launched last week with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.
-
New Dermatology Company Resilia Pharmaceuticals Begins Operations
12/28/2020
Specialty Pharma Company Selling Ecoza® (econazole nitrate) topical foam, 1%, Recedo® Topical Gel, Neosalus® Cream, Neosalus® Foam, and Neocera® Advanced Cream Is Focused on Patient Outcomes
-
Motility Medical Commences Human Trials for New Medical Device to Treat Constipation
12/21/2020
Motility Medical ( http://www.motilitymedical.com ), a biotech startup that is developing a novel neuromodulation device to treat the millions of Americans who suffer from chronic constipation (most significantly people living with neurogenic bowel from a spinal cord injury), has started human trials for their prototype device. The
-
Digital Therapeutics Startup S-Alpha Therapeutics Raises $2.7M in Seed Funding
12/16/2020
On November 20 th , S-Alpha Therapeutics (“S-Alpha” Seung Eun Choi, CEO), a digital therapeutics startup, completed a $2.7 Million USD (3 Billion KRW) seed round of funding from Hana Ventures, STIC Ventures, AJU IB Investment, SJ Investment Partners, and TONY Investment. This seed round follows an initial strategic investment from LegoChem Biosciences in February 2020. This press release features multimedia. View the full release